The pharmacovigilance plan is Part III of the European Risk Management Plan and describes the specific activities used to further characterize or quantify the safety concerns of a medicinal product. It builds upon the safety specification and also includes post-authorisation safety studies, insofar as they are required for open safety questions. Its purpose is gaining knowledge about risks, rather than the immediate limitation of their consequences.
From safety concerns to activities
The plan links every relevant important identified or potential risk, as well as missing information, to a justified pharmacovigilance activity. Routine monitoring may suffice if the existing data do not require additional measures. If there is a specific need for knowledge, additional activities such as a PASS, registries, targeted data collection, or supplementary analyses are considered. The measure must answer a precise question instead of merely collecting more data without a defined purpose.
For each additional activity, the objective, data source, population, timeframe, and expected contribution to the risk assessment should be transparent. A PASS can, for example, investigate frequency, severity, risk factors, or the effectiveness of risk minimization. However, it is not to be equated with the pharmacovigilance plan: the plan assigns all intended activities to the safety concerns, while an individual study is just one instrument among them.
Documentation and updates
The RMP makes it visible why an activity is proposed, continued, or terminated. New results can turn a potential risk into an identified risk, close gaps in missing information, or refute the need for additional investigation. Such changes must be consistently reflected in the safety specification, the plan, and the summary of safety concerns. Not every standard evaluation is to be designated as an additional activity; this distinction protects against a cluttered plan without regulatory added value.
Planning does not end with authorization. It accompanies product use and is adjusted when exposure, patient groups, indications, or risk profiles change. In the event of new safety questions, an existing study can be adapted, a new investigation may become necessary, or existing routine monitoring may be sufficient after professional review. The justification must link the measure to the respective knowledge deficit.
Distinction from risk minimization and PASS
The pharmacovigilance plan generates or consolidates knowledge; Part V of the RMP, by contrast, reduces the probability or severity of harm through risk minimization measures. Training, a patient alert card, or controlled distribution can guide behavior, but they do not automatically answer the question regarding the actual frequency of a risk. Both parts can refer to the same safety concern, yet they fulfill different functions.
The Post-Authorisation Safety Study is one possible additional pharmacovigilance activity. It can be included in the plan, but the plan contains more than one PASS and can exist without a PASS. Conversely, a study outside the RMP does not automatically belong to the pharmacovigilance plan. The decisive factor is the justified link to a safety concern and the role of the study in its further characterization.
Furthermore, the activity must be linked to a measurable knowledge objective. A phrase such as “continue to monitor” is insufficient if it remains unclear which information, given which result, will change the risk assessment. For data from registries or secondary databases, the validity of exposure, reliability of diagnosis, and possible biases must be considered in advance. The plan can also determine which interim or final results trigger an RMP update. In this way, a mere obligation to monitor becomes a manageable knowledge path for a specific product issue.
When planning additional activities, it must also be clarified whether an independent data source is available and whether the proposed design reflects the relevant comparator group. Without these preliminary considerations, a formally conducted study may leave the central risk question unanswered and thus fail to meaningfully develop the RMP.
Significance for clinical trials
Trials often provide the data from which pharmacovigilance plan questions later arise: rare events, limited long-term exposure, or lack of experience in specific populations. It should already be clear during development which safety endpoints, follow-up times, and data elements will enable a later assessment. Transitions between interventional trials and post-authorisation observational studies require particularly clear responsibilities for data quality and safety reporting.
Full-service CROs like Mediconomics support the formulation of risk-related study questions, PASS protocols, feasibility, and study start-up, as well as safety and data management plans. They can align RMP tables with study milestones and prepare reporting so that results are traced back to the knowledge gap defined in the plan.
Frequently Asked Questions (FAQ)
Does every safety concern have to trigger a new study?
No. The plan can justify that routine pharmacovigilance is sufficient or that another activity answers the question more appropriately.
What does a PASS investigate within the pharmacovigilance plan?
It can, for example, investigate frequency, severity, risk factors, or the effectiveness of risk minimization for a specified safety concern.
Why is the plan not identical to Part V of the RMP?
Part III serves to gain further knowledge, while Part V describes specific measures to reduce a risk.
Regulatory References
- EMA Guideline GVP, Module V – categorizes the pharmacovigilance plan as Part III of the RMP.
- EU RMP Format, Rev. 2.0.1 – requires the presentation of pharmacovigilance activities and PASS.
- Regulation (EU) No 520/2012, Article 34 – contains requirements for post-authorisation studies.